Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

GlaxoSmithKline, Nabi to Develop Smoking Vaccine

By Pharmaceutical Processing | November 16, 2009

NEW YORK (AP) — GlaxoSmithKline PLC and Nabi Biopharmaceuticals said Monday they will work together to develop vaccines to help smokers give up the habit, in a deal that could be worth more than $500 million. Nabi is developing a vaccine called NicVAX, which is intended to train the immune system to make antibodies that will attach themselves to nicotine. With the antibodies stuck to them, the nicotine molecules will not be able to reach the brain. The companies say that will block the pleasurable effects of nicotine. In the deal, Nabi will get $40 million upfront and complete testing of NicVAX. GlaxoSmithKline, which is based in London, will also start developing a second-generation version of the vaccine. Nabi, of Rockville, Md., is running one late-stage clinical study of NicVAX and plans to start another one. If testing is successful, GlaxoSmithKline will be responsible for getting the vaccine approved by regulators, and will market the drug if it is approved. Nabi could receive milestone payments for successful testing, regulatory approval and sales targets, as well as royalties of more than 10 percent on sales. The companies said those payments could reach more than $500 million. The deal is expected to close in the first quarter of 2010. The companies said there are about 1.2 billion smokers in the world, and smoking causes 5.4 million deaths per year.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE